CLINICAL TRIALS PROFILE FOR INCIVEK

505(b)(2) Clinical Trials for INCIVEK

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT01511432 ↗	A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects	Completed	Vertex Pharmaceuticals Incorporated	Phase 1	2012-01-01	The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.

All Clinical Trials for INCIVEK

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01355289 ↗	Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501	Completed	Eisai Inc.	Phase 2	2011-11-01	To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment.
NCT01459913 ↗	Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype	Terminated	Vertex Pharmaceuticals Incorporated	Phase 3	2011-11-01	The purpose of this study is to evaluate if a 12-week total regimen of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) (T12/PR12) is safe and effective in subjects who have the interleukin-28B (IL28B) CC genotype. The subjects enrolled in this study will have chronic hepatitis C virus (HCV) infection and will not have cirrhosis of the liver.
NCT01511432 ↗	A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects	Completed	Vertex Pharmaceuticals Incorporated	Phase 1	2012-01-01	The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.
NCT01581138 ↗	VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C	Completed	Vertex Pharmaceuticals Incorporated	Phase 2	2012-07-01	The purpose of this study is to evaluate the efficacy and safety of two all oral regimens in subjects who have chronic hepatitis C and have not received treatment yet.
NCT01592006 ↗	Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients	Terminated	University of Chicago	Phase 4	2012-04-01	Patients are being asked to be part of this study because they are a liver transplant recipient and have the Hepatitis C Virus (HCV). Current routine treatment for HCV for liver transplant patients includes taking two medications called pegylated interferon alfa-2a (Pegasys®) and ribavirin. Patients Pegasys and ribavirin are FDA approved for the treatment of HCV. This study will evaluate the safety and efficacy of adding a third drug called telaprevir for the experimental treatment of HCV in liver transplant patients. The combination of Pegasys, ribavirin and telaprevir is currently FDA approved for the treatment of HCV, but is specifically not FDA approved for HCV patients who have had a liver transplant. This is because more information is needed about possible drug interactions between telaprevir and cyclosporine, or telaprevir and tacrolimus-based immunosuppressive drugs, which are typically part of routine care for transplant patients. Studies have shown that the addition of telaprevir greatly increases the efficacy of Pegasys and ribavirin for the treatment of HCV. However, these studies did not include adequate information on transplant patients due to the potential drug interactions. The investigators hope to gather more information about the safety and efficacy of telaprevir given in combination with Pegasys and ribavirin in the liver transplant patients who have HCV that is not well controlled with Pegasys and ribavirin alone.

Clinical Trial Conditions for INCIVEK

Condition Name

Condition Name for INCIVEK
Intervention	Trials
Hepatitis C, Chronic	3
Hepatitis C	3
Chronic Hepatitis C	2
Hepatitis C Virus	1

Condition MeSH

Condition MeSH for INCIVEK
Intervention	Trials
Hepatitis C	11
Hepatitis	10
Hepatitis C, Chronic	7
Hepatitis A	7

Clinical Trial Locations for INCIVEK

Trials by Country

Trials by Country for INCIVEK
Location	Trials
United States	60
Canada	8
Brazil	5
Germany	2
Austria	2

Trials by US State

Trials by US State for INCIVEK
Location	Trials
Texas	6
California	5
Virginia	4
Wisconsin	3
Pennsylvania	3

Clinical Trial Progress for INCIVEK

Clinical Trial Phase

Clinical Trial Phase for INCIVEK
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	3
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for INCIVEK
Clinical Trial Phase	Trials
Completed	6
Terminated	3
Withdrawn	2

Clinical Trial Sponsors for INCIVEK

Sponsor Name

Sponsor Name for INCIVEK
Sponsor	Trials
Vertex Pharmaceuticals Incorporated	5
Santaris Pharma A/S	2
Massachusetts General Hospital	1

Sponsor Type

Sponsor Type for INCIVEK
Sponsor	Trials
Industry	9
Other	4
U.S. Fed	1

Clinical Trials Update, Market Analysis, and Projection for Incivek (Telaprevir)

Last updated: October 28, 2025

---

Introduction

Incivek (telaprevir), developed by Vertex Pharmaceuticals, received FDA approval in 2011 for treating chronic hepatitis C virus (HCV) infection, specifically genotype 1. As a protease inhibitor, Incivek represented a significant advancement in HCV therapy, offering improved cure rates over previous interferon-based regimens. Since its launch, its lifecycle has been shaped by subsequent treatment advances, shifting market dynamics, and evolving clinical trial landscapes. This analysis synthesizes recent clinical trial updates, examines the current market environment, and projects future market trajectories for Incivek.

---

Clinical Trials Landscape for Incivek

Recent Clinical Trial Developments

The clinical research landscape for telaprevir has predominantly transitioned from initial approvals toward comparative effectiveness and safety assessments within newer regimens, especially as direct-acting antivirals (DAAs) have revolutionized HCV therapy.

• Combination Therapy Studies: Recent trials focus on integrating telaprevir into combination regimens with newer DAAs to evaluate efficacy, safety, and resistance profiles. For example, the phase 3 ADVANCE and AMPLIFY studies initially established telaprevir combined with pegylated interferon and ribavirin. Subsequent trials have assessed its role within interferon-free regimens, although its standalone development has diminished.

• Resistance and Safety Trials: Studies investigate resistance development during telaprevir treatment. Data indicate that resistance-associated variants can emerge, especially with adherence lapses, leading to compromised efficacy. Long-term safety profiles continue to be monitored through post-marketing surveillance.

• Regulatory and Post-Marketing Studies: The FDA and EMA have mandated post-marketing studies to assess long-term safety, particularly concerning anemia, rash, and fatigue—adverse effects associated with telaprevir.

Clinical Trial Status

Currently, there are negligible active clinical trials testing Incivek as a primary treatment. Most ongoing studies are post-marketing observational, focusing on real-world effectiveness and safety. The rise of newer, all-oral, interferon-free regimens (e.g., sofosbuvir-based combinations) has rendered telaprevir largely obsolete in clinical practice and research.

---

Market Analysis

Market Introduction and Peak

At its launch, Incivek rapidly captured a significant share of the HCV treatment market due to its superior efficacy relative to interferon monotherapy. During 2012-2014, it accounted for approximately 20-25% of the global HCV treatment market, driven by patent exclusivity and early adoption.

Market Challenges and Decline

The landscape shifted as newer DAAs, such as simeprevir, sofosbuvir, daclatasvir, ledipasvir, and glecaprevir, entered the market, offering:

• Simplified dosing
• Shorter treatment courses
• Higher cure rates (>95%)
• Fewer adverse effects

These improvements led to rapid declines in Incivek's market share. By 2018, the drug's utilization had decreased sharply, constrained to niche markets or salvage therapy in resistant cases.

Regulatory Withdrawals and Market Exit

In 2018, Vertex announced the voluntary withdrawal of Incivek from the market. This decision reflected:

• The commercial decline due to competition from newer DAAs
• Challenges in maintaining profitability
• The comprehensive shift toward all-oral, interferon-free regimens

Despite its withdrawal, some formulations persisted in certain markets, primarily through generic channels or off-label use.

Current Market Environment

Today, the global HCV drug market is dominated by all-oral, pan-genotypic regimens. The market size for telaprevir-specific treatments remains minimal, primarily limited to:

• Resistance cases where newer therapies fail
• Developing markets with limited access to newer DAAs
• Research contexts examining resistance or combination therapies

The overall global HCV therapeutics market is projected to grow at a CAGR of 8-10% through 2030, driven by increasing screening, diagnosis, and treatment efforts, particularly in under-served regions [1].

---

Market Projection and Future Outlook

Short to Mid-term

Given the market exit and the dominance of newer DAAs, Incivek's market share is negligible. Future projections suggest:

• Complete market removal: No active commercialization expected post-2025.
• Limited residual use: In select resistance or resource-limited settings, residual interest persists, but unlikely to impact market projections significantly.
• Potential for generic manufacturing: In certain regions, generic versions may remain available, although these are also phased out with newer standards of care.

Long-term Trends

The global HCV market is shifting toward pan-genotypic, short-duration, oral regimens with minimal side effects. This evolution renders telaprevir obsolete in treatment algorithms.

However, ongoing research into resistance profiling and innovative delivery mechanisms could theoretically revive interest in telaprevir or similar protease inhibitors as adjuncts or in combination with next-generation agents. Nevertheless, current therapeutics development pipelines suggest minimal post-market growth potential for Incivek.

Market Drivers

Key factors influencing future specifics include:

• Global health initiatives to eradicate HCV, especially in developing countries
• Access and affordability of newer DAAs
• Resistance management strategies for refractory cases
• Patent landscape modifications and generic industry dynamics

Based on these, the comprehensive outlook indicates a declining presence, supplanted by newer therapies, with scant prospect for a significant rebound.

---

Key Takeaways

• Clinical Trials: Most recent efforts focus on resistance monitoring and integrating telaprevir into new regimens, but active clinical trials for Incivek have ceased, reflecting its market obsolescence.
• Market Dynamics: Incivek experienced rapid market uptake post-approval but faced irreversible decline following the advent of superior, safer, and more convenient DAA regimens.
• Regulatory and Commercial Exit: Vertex's voluntary withdrawal in 2018 marked the end of Incivek’s commercial lifecycle in major markets.
• Future Outlook: The global HCV drug market is dominated by pan-genotypic, all-oral therapies, with negligible role for telaprevir. Residual use may persist in niche applications but is unlikely to meaningfully impact future market trends.
• Strategic Implication: Companies investing in HCV therapeutics should prioritize innovation in pan-genotypic, short-duration treatments and resistance management rather than revisiting protease inhibitors like Incivek.

---

FAQs

1. Is Incivek still available on the global market?
   No. Vertex withdrew Incivek from the market in 2018 due to declining demand and shifts toward newer therapies.

2. Are there ongoing clinical trials involving telaprevir?
   Most clinical trials involving telaprevir have been concluded; current efforts focus on resistance and combination therapies, with no active trials testing Incivek as a primary treatment.

3. What are the main reasons for Incivek’s decline?
   The advent of all-oral, highly effective, and better-tolerated DAAs rendered telaprevir obsolete, leading to market withdrawal and discontinuation in clinical practice.

4. Could Incivek be repurposed or reformulated for future use?
   Unlikely, given the current therapeutic landscape and lack of clinical interest or supportive research for telaprevir as a monotherapy or component in new regimens.

5. What lessons can pharmaceutical companies learn from Incivek’s market trajectory?
   Invest in innovative, patient-friendly, and pan-genotypic treatments early, and monitor evolving clinical guidelines to avoid obsolescence. Also, plan for rapid lifecycle management to adapt to paradigm shifts in disease management.

---

References

1. Global Hepatitis C Market & Pipeline Analysis. (2022). Pharma Intelligence.
2. FDA Approves Incivek (telaprevir) for Chronic Hepatitis C Virus Genotype 1 Infection. U.S. Food and Drug Administration, 2011.
3. Market Dynamics of Hepatitis C Treatments. (2021). IMS Health Reports.
4. Resistance and Safety Data in Telaprevir Regimens. (2019). Journal of Hepatology.

---

Disclaimer: This analysis reflects publicly available data and industry insights as of early 2023. Market conditions and clinical landscapes evolve rapidly; readers should consult additional sources for the latest developments.